

EYEPOINT PHARMACEUTICALS

CASE OVERVIEW

Status: Investigating
Company Name: EyePoint Pharmaceuticals
Ticker: EYPT
Related Attorneys: Thomas W. Elrod
Related Practices: Securities

On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU, revealing that DURAVYU missed the prespecified primary endpoint—change in best-corrected visual acuity versus on-label aflibercept. Previously, on March 25, 2026, President and CEO Jay S. Duker had stated they were “highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons.” On June 9, he reiterated that they “remain quite confident and quite optimistic in the results and we think we can make a difference for patients.” On this news, the Company’s stock price declined \$9.88, or 67%, to close at \$4.87 on August 17, 2026.